ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ERYP
Previous Symbol
CUSIPN/A
Phone33-4-78-74-44-38
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$11.98 per share
Price / Book0.55
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees114
Outstanding Shares17,930,000
Market Cap$127.88 million
OptionableNot Optionable
Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions
What is Erytech Pharma's stock symbol?
Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."
What price target have analysts set for ERYP?
2 analysts have issued 1 year price targets for Erytech Pharma's shares. Their forecasts range from $43.00 to $43.00. On average, they anticipate Erytech Pharma's stock price to reach $43.00 in the next year. This suggests a possible upside of 554.5% from the stock's current price. View Analyst Price Targets for Erytech Pharma.
What is the consensus analysts' recommendation for Erytech Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Erytech Pharma.
Has Erytech Pharma been receiving favorable news coverage?
News articles about ERYP stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Erytech Pharma earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of Erytech Pharma's key competitors?
Some companies that are related to Erytech Pharma include Scholar Rock (SRRK), Mesoblast (MESO), Replimune Group (REPL), PDL BioPharma (PDLI), Nightstar Therapeutics (NITE), Voyager Therapeutics (VYGR), La Jolla Pharmaceutical (LJPC), CASI Pharmaceuticals (CASI), MeiraGTx (MGTX), Translate Bio (TBIO), LogicBio Therapeutics (LOGC), Cellular Biomedicine Group (CBMG), Krystal Biotech (KRYS), Sutro Biopharma (STRO) and Agenus (AGEN).
Who are Erytech Pharma's key executives?
Erytech Pharma's management team includes the folowing people:
- Mr. Gil Beyen, Chairman & CEO (Age 56)
- Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 39)
- Mr. Eric Soyer, CFO & COO (Age 52)
- Dr. Alexander Scheer, Chief Scientific Officer (Age 56)
- Naomi Eichenbaum, Director Investor Relations
When did Erytech Pharma IPO?
(ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.
Who are Erytech Pharma's major shareholders?
Erytech Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (6.06%), Sphera Funds Management LTD. (0.67%) and EcoR1 Capital LLC (0.39%).
Which institutional investors are selling Erytech Pharma stock?
ERYP stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP and EcoR1 Capital LLC.
Which institutional investors are buying Erytech Pharma stock?
ERYP stock was acquired by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD..
How do I buy shares of Erytech Pharma?
Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Erytech Pharma's stock price today?
One share of ERYP stock can currently be purchased for approximately $6.57.
How big of a company is Erytech Pharma?
Erytech Pharma has a market capitalization of $127.88 million. The company earns $-37,890,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis. Erytech Pharma employs 114 workers across the globe.
What is Erytech Pharma's official website?
How can I contact Erytech Pharma?
Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected]
MarketBeat Community Rating for Erytech Pharma (NASDAQ ERYP)
MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote "Outperform" if you believe ERYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
